Ascletis Pharma (HKSE:01672) EV-to-EBIT : 8.64 (As of Jun. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ascletis Pharma's Enterprise Value is HK$-1,366.89 Mil. Ascletis Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-158.13 Mil. Therefore, Ascletis Pharma's EV-to-EBIT for today is 8.64.

The historical rank and industry rank for Ascletis Pharma's EV-to-EBIT or its related term are showing as below:

HKSE:01672' s EV-to-EBIT Range Over the Past 10 Years
Min: -145.47 Med: 0.22 Max: 44.19
Current: 8.71

During the past 8 years, the highest EV-to-EBIT of Ascletis Pharma was 44.19. The lowest was -145.47. And the median was 0.22.

HKSE:01672's EV-to-EBIT is ranked better than
53.18% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs HKSE:01672: 8.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ascletis Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was HK$-983.46 Mil. Ascletis Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-158.13 Mil. Ascletis Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 16.08%.

Ascletis Pharma EV-to-EBIT Historical Data

The historical data trend for Ascletis Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma EV-to-EBIT Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

0.34

0.18

-2.23

-6.79

6.22

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial										-2.23	-	-6.79	-	6.22

Competitive Comparison of Ascletis Pharma's EV-to-EBIT

For the Biotechnology subindustry, Ascletis Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's EV-to-EBIT falls into.

Ascletis Pharma EV-to-EBIT Calculation

Ascletis Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-1366.886	/	-158.128
	=	8.64

Ascletis Pharma's current Enterprise Value is HK$-1,366.89 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-158.13 Mil.

Ascletis Pharma (HKSE:01672) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ascletis Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-158.128	/	-983.4618
	=	16.08 %

Ascletis Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was HK$-983.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-158.13 Mil.

Ascletis Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Executives

Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines